In December 2023, a 12-year-old boy named Kendrick Cromer became the first person in the United States to receive a newly approved treatment for sickle cell disease. The therapy wasn't a drug in the traditional sense. It was a precise genetic edit made to his own blood stem cells—a fix so elegant that it had been dismissed as science fiction just a decade earlier.
That treatment, Casgevy, marked the first FDA-approved CRISPR therapy in American history. It wasn't just a milestone for sickle cell patients; it was the moment gene editing stopped being a laboratory curiosity and became clinical medicine.
The journey from a curious bacterial immune system to a $2.2 million commercial therapy took just over a decade—lightning speed by pharmaceutical standards. By 2026, that pace has only accelerated. More than 100 clinical trials are now testing CRISPR-based therapies worldwide, spanning oncology, rare genetic diseases, and even infectious conditions like HIV. The global CRISPR market is projected to reach $8.5 billion this year.
But with this momentum comes hard questions. Who can afford these treatments? How do we ensure safety over a lifetime? And where do we draw the line between healing disease and editing human heredity?
This is the state of CRISPR in 2026: transformative, promising, and deeply complicated.
CRISPR-Cas9 is often described as "molecular scissors," but that undersells its sophistication. The system has two components: a guide RNA that locates a specific DNA sequence, and the Cas9 enzyme that cuts it. When the cut is made, the cell's natural repair mechanisms kick in—either by stitching the ends together (disabling a gene) or by using a provided template to insert new genetic information.
The story begins in bacteria. Microbes face constant viral attacks, and CRISPR (short for Clustered Regularly Interspaced Short Palindromic Repeats) evolved as their adaptive immune system. When a virus infects a bacterium, the microbe captures a snippet of viral DNA and stores it in its own genome. On subsequent infections, it uses that stored sequence to produce RNA guides that direct Cas enzymes to chop up the invader's DNA.
Scientists Jennifer Doudna and Emmanuelle Charpentier recognized in 2012 that this system could be reprogrammed. Instead of targeting viral DNA, the guide RNA could be designed to target any gene in any organism. They won the Nobel Prize in Chemistry in 2020 for that insight.
The original CRISPR-Cas9 makes double-strand breaks—clean cuts, but cuts nonetheless. This can lead to unintended mutations if the cell repairs the damage imprecisely. To address this, researchers developed refinements:
These tools expand what's treatable, particularly for conditions caused by single-point mutations.
Somatic editing targets non-reproductive cells—the edit affects the patient but is not passed to offspring. Germline editing alters sperm, eggs, or embryos, meaning the change is heritable. The latter remains highly controversial and is effectively banned in most countries.
Off-target effects refer to unintended edits at sites other than the target sequence. While modern guide RNA design has dramatically reduced these risks, they remain a focus of long-term safety monitoring.
Key Takeaway: CRISPR is a programmable gene-editing system derived from bacteria. Newer tools like base editing and prime editing offer greater precision than the original Cas9, expanding the range of treatable conditions.
Casgevy (exagamglogene autotemcel) addresses two inherited blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia. Both conditions stem from mutations in the beta-globin gene, which produces a component of hemoglobin.
Sickle cell disease affects roughly 100,000 Americans, predominantly of African descent. The misshapen red blood cells cause chronic pain, organ damage, and reduced life expectancy. Beta-thalassemia, more common in Mediterranean and Asian populations, impairs hemoglobin production so severely that patients require regular blood transfusions.
Casgevy doesn't repair the mutated beta-globin gene directly. Instead, it takes a more indirect route. The therapy edits a gene called BCL11A, which normally suppresses fetal hemoglobin production after birth. By disabling BCL11A in a patient's hematopoietic stem cells, Casgevy reactivates fetal hemoglobin—a form that isn't affected by the disease-causing mutations.
The process is intensive: stem cells are harvested from the patient's bone marrow, edited in a laboratory, and then infused back after the patient receives chemotherapy to clear space in the bone marrow. It's a one-time treatment, but the procedure requires weeks of hospitalization and recovery.
The FDA approved Casgevy in December 2023, following clinical trials that showed 28 of 30 sickle cell patients remained free of severe pain crises for at least 18 months after treatment. The agency also approved it for transfusion-dependent beta-thalassemia in January 2024.
The significance extends beyond the specific diseases. Casgevy proved that CRISPR could work safely in humans at scale, paving the way for the pipeline that followed.
Casgevy's list price is $2.2 million per treatment course in the U.S. That's cheaper than a lifetime of sickle cell care (estimated at $4–6 million per patient), but it's still out of reach for most health systems globally.
Insurance coverage is improving: Medicare and most private insurers now cover the treatment. But in sub-Saharan Africa, where sickle cell disease is most prevalent, the therapy is essentially unavailable. This disparity—between where the disease is most common and where the treatment is accessible—remains one of CRISPR medicine's most uncomfortable truths.
Key Takeaway: Casgevy works by reactivating fetal hemoglobin through a precise edit to the BCL11A gene. It's a one-time cure but costs $2.2 million, raising serious questions about global access.
CAR-T therapy has been used since 2017 to treat certain blood cancers. The approach involves harvesting a patient's T cells, genetically engineering them to recognize cancer cells, and infusing them back. But traditional CAR-T uses viral vectors to insert the CAR gene randomly into the genome—a process that carries a small risk of insertional mutagenesis.
CRISPR offers a more controlled alternative. Instead of random insertion, CRISPR can place the CAR gene at a precise location. It can also knock out genes that would otherwise inhibit the engineered T cells.
CTX110, developed by CRISPR Therapeutics, targets CD19, a protein found on B-cell lymphomas. Unlike traditional CAR-T, which uses each patient's own cells (a time-consuming, expensive process), CTX110 uses healthy donor cells. CRISPR is used to:
This creates an "off-the-shelf" therapy that can be manufactured in advance and given to any eligible patient.
In clinical trials, CTX110 achieved a 67% overall response rate in patients with relapsed or refractory B-cell lymphoma—patients who had exhausted other treatment options. While the trial wasn't designed as a head-to-head comparison, these results are comparable to traditional autologous CAR-T therapies, with the advantage of immediate availability.
The off-the-shelf model addresses two major limitations of current CAR-T: manufacturing time (weeks versus days) and cost (which can exceed $500,000 for the therapy alone). It also allows for repeat dosing if the first infusion doesn't achieve remission.
Challenges remain. Donor cells can persist for shorter periods than patient-derived cells, potentially increasing relapse rates. And solid tumors—which represent the majority of cancers—have proven more resistant to CAR-T approaches due to the immunosuppressive tumor microenvironment.
Researchers are now using CRISPR to engineer T cells that resist this suppression, for example by knocking out PD-1, an immune checkpoint that tumors exploit to evade attack.
Key Takeaway: CRISPR enables "off-the-shelf" CAR-T therapies using donor cells, dramatically reducing cost and wait times. Early results show response rates comparable to traditional approaches.
Hereditary angioedema is a rare genetic condition causing recurrent, potentially life-threatening swelling attacks. It's caused by mutations that lead to overproduction of kallikrein, a protein involved in inflammation.
NTLA-2002, developed by Intellia Therapeutics, uses CRISPR-Cas9 to edit the KLKB1 gene in liver cells, reducing kallikrein production. In Phase 2 trials, the therapy reduced attack rates by 95%—a dramatic improvement for a condition that can cause airway obstruction.
What makes NTLA-2002 notable is its delivery method. Unlike Casgevy, which requires harvesting and re-infusing cells, NTLA-2002 is administered intravenously. The CRISPR components are packaged in lipid nanoparticles that naturally accumulate in the liver—the same delivery technology used in mRNA COVID-19 vaccines.
The eye offers several advantages for gene therapy: it's immune-privileged (reducing rejection risk), easily accessible for injection, and requires only small amounts of therapeutic agent.
EDIT-101, developed by Editas Medicine, targets Leber congenital amaurosis, a rare inherited retinal disease caused by mutations in the CEP290 gene. The therapy is delivered via subretinal injection and aims to restore vision by correcting the specific mutation. Early clinical results have shown measurable improvements in light sensitivity and visual function in some patients.
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, the largest gene in the human genome. Its size makes traditional gene therapy (which uses viruses to deliver a functional copy) challenging.
CRISPR approaches instead aim to excise specific mutated exons, restoring the reading frame and allowing production of a shortened but functional dystrophin protein. This "exon skipping" strategy has shown promise in animal models, and human trials are underway, though delivery to muscle tissue remains a significant hurdle.
Antiretroviral therapy can suppress HIV to undetectable levels, but the virus integrates its DNA into host cells and persists in reservoirs. CRISPR offers the theoretical possibility of excising integrated viral DNA entirely.
Researchers have demonstrated this approach in animal models, using CRISPR to cut out HIV proviral DNA from infected cells. Human trials are in early stages, and significant challenges remain—primarily delivering CRISPR to all infected cells, including those in hard-to-reach reservoirs like the brain and gut-associated lymphoid tissue.
Key Takeaway: CRISPR is being tested for a wide range of conditions beyond blood disorders, including rare genetic diseases, muscular dystrophy, and HIV. Delivery methods vary from cell harvesting to targeted nanoparticles.
Several CRISPR therapies are in late-stage development and could receive FDA approval in the near term:
The global CRISPR gene editing market is projected to reach $8.5 billion by 2026, according to MarketsandMarkets. This growth is driven not just by therapeutics but also by research tools, diagnostics, and agricultural applications.
The competitive landscape is consolidating. Major pharmaceutical companies have partnered with or acquired CRISPR startups. Regulatory pathways are becoming clearer, with the FDA establishing specific guidance for gene editing products.
Base editing and prime editing are moving from academic labs into clinical development. These tools offer several advantages:
For example, base editing is being explored for sickle cell disease using a different strategy than Casgevy—directly correcting the sickle mutation rather than reactivating fetal hemoglobin. This approach could potentially achieve the same clinical benefit with a simpler editing process.
Key Takeaway: The CRISPR pipeline is robust, with therapies for amyloidosis, hereditary angioedema, and additional blood disorders nearing approval. Next-generation tools promise even greater precision and broader applicability.
CRISPR's ability to recognize specific DNA sequences with high accuracy makes it ideal for diagnostic applications. The SHERLOCK system (Specific High-sensitivity Enzymatic Reporter unLOCKing) uses CRISPR-Cas13 to detect nucleic acids and produce a fluorescent signal.
In 2020, SHERLOCK-based tests for COVID-19 demonstrated 100% specificity in early studies—meaning no false positives. In 2025, the FDA approved a CRISPR-based diagnostic test for infectious diseases, enabling rapid point-of-care detection without laboratory equipment.
The advantages over traditional PCR testing are significant: CRISPR diagnostics can be freeze-dried for stability at room temperature, require minimal equipment, and can distinguish between closely related viral strains.
CRISPR-edited crops are already reaching consumers, though regulatory frameworks vary by country.
The first CRISPR-edited food to reach the U.S. market was a non-browning mushroom, approved by the USDA in 2016 because it didn't contain foreign DNA. Since then, CRISPR has been used to develop:
The regulatory landscape is evolving. In the U.S., the USDA has stated it will not regulate plants edited through methods like CRISPR if the changes could have been achieved through traditional breeding. The EU, which previously imposed strict regulations on genetically modified organisms, has proposed more permissive rules for certain gene-edited crops.
Key Takeaway: Beyond medicine, CRISPR is transforming diagnostics and agriculture. CRISPR-based tests offer rapid, accurate detection of infectious diseases, while edited crops promise improved resilience and nutrition.
Despite improved guide RNA design, off-target edits remain a concern. A single unintended mutation in a tumor suppressor gene could, in theory, increase cancer risk years later.
Regulatory agencies require long-term follow-up for CRISPR therapy recipients—typically 15 years or more—to monitor for delayed adverse effects. Early data from Casgevy patients are reassuring, but the longest follow-up period is still less than a decade.
Somatic editing—the kind used in approved therapies—affects only the patient. Germline editing, which alters embryos or reproductive cells, would produce changes inherited by future generations.
In 2018, Chinese scientist He Jiankui announced the birth of twin girls whose CCR5 gene he had edited to potentially confer HIV resistance. The scientific community condemned the work as premature and unethical, and He was sentenced to prison.
The consensus remains firmly against germline editing for clinical use. But the technology exists, and as it improves, the pressure to use it for preventing devastating genetic diseases will intensify. A 2025 survey across 20 countries found that 58% of respondents supported germline editing to prevent serious diseases—but only 12% supported it for enhancement purposes.
Even with insurance coverage, CRISPR therapies impose significant burdens on patients and healthcare systems. The intensive procedures required—stem cell harvesting, chemotherapy conditioning, extended hospitalization—make these treatments inaccessible to many.
Global disparities are stark. Sickle cell disease is most prevalent in sub-Saharan Africa, where Casgevy is unavailable. Efforts to develop lower-cost CRISPR therapies using in vivo delivery (injecting editing components directly into the body rather than harvesting and editing cells) could reduce costs, but these approaches are years from approval.
The FDA has established a framework for evaluating gene editing therapies, requiring evidence of targeting accuracy, efficacy, and durability. Similar frameworks exist in Europe and Japan. But harmonization across countries remains incomplete, creating challenges for global clinical trials and market access.
Key Takeaway: While CRISPR therapies are transforming medicine, significant challenges remain—ensuring long-term safety, navigating ethical debates around germline editing, and addressing the high costs that limit global access.
In 2023, the first CRISPR therapy became a clinical reality. By 2026, that single approval has expanded into a pipeline of more than 100 clinical trials spanning oncology, rare diseases, and infectious conditions. The technology has moved from "will it work?" to "how well does it work, and for whom?"
The next decade will determine whether CRISPR medicine fulfills its promise of accessible, curative treatments—or remains a technology available primarily to those in wealthy countries with sophisticated healthcare systems.
The scientific challenges are largely being met. The ethical and economic ones are not. Balancing innovation with responsibility means ensuring that the benefits of gene editing don't accrue only to those who can afford them, and that the power to rewrite our genetic code is used to heal disease, not to engineer advantage.
CRISPR has given us a remarkable tool. What we do with it is up to us.
CRISPR is a gene-editing system derived from a bacterial immune defense mechanism. It uses a guide RNA to locate a specific DNA sequence and the Cas9 enzyme to cut it. The cell's natural repair processes then either disable the gene or incorporate new genetic material.
Casgevy (exagamglogene autotemcel), approved in December 2023 for sickle cell disease and later for beta-thalassemia. It works by editing a patient's own blood stem cells to reactivate fetal hemoglobin production.
For approved therapies, the evidence to date indicates acceptable safety profiles, with patients monitored for 15 years or more for delayed effects. Off-target edits remain a concern, though next-generation tools like base editing reduce this risk.
For certain conditions—primarily blood disorders—CRISPR has demonstrated curative potential. For others, including muscular dystrophy and HIV, research is ongoing and significant challenges remain.
Somatic editing affects non-reproductive cells and is not inherited. Germline editing alters embryos or reproductive cells, making changes heritable. Germline editing is effectively banned in most countries and remains ethically controversial.
Casgevy is priced at $2.2 million per treatment course in the U.S. Other therapies are expected to have similar pricing. Costs are lower in some countries but remain prohibitive for most health systems globally.
Key concerns include equitable access to treatment, the potential for germline editing and "designer babies," long-term safety monitoring, and the environmental implications of gene-edited organisms.
Yes. CRISPR-edited CAR-T therapies, such as CTX110, are in clinical trials for B-cell lymphomas, showing response rates around 67% in relapsed/refractory patients. These therapies use donor cells, reducing cost and wait times.
CRISPR is used to develop crops with improved traits, including drought resistance, disease resistance, and enhanced nutritional content. Regulatory frameworks vary by country, with the U.S. generally taking a permissive approach.
Expect continued expansion into new disease areas, refinement of delivery methods, and increasing use of base and prime editing. The next major challenge is reducing costs and ensuring equitable global access.
If you found this deep dive into CRISPR's medical revolution insightful, share it with someone curious about the future of genetics. For more science explainers, subscribe to our newsletter and stay updated on the latest breakthroughs.